Special Issue

Green Antimicrobials in Biomedical Engineering: Recent Advances Proposal

Message from the Guest Editor

In recent years, the increasing awareness of climate change and high pollution levels has expanded our sense of ecological responsibility. The pharmaceutical industry is one of the most polluting industries. Additionally, new environmentally friendly approaches to deal with the growing concern associated with antimicrobial-resistant bacteria are also in great demand. The excessive consumption and misuse of pharmaceutical products, namely antibiotics, have accelerated the increase in such pathogens responsible for compromising global health, not only that of humans but of all living systems. Considering our natural resources are in great danger, finding green and less environmentally impactful alternatives for combating these resistant microbials is imperative. From green chemistries and natural extracts to waste products, the sources for these alternative antimicrobial agents can be immense and their impact of great importance for future generations. This Special Issue seeks to further our understanding of the antimicrobial action of specialized molecules derived from green and ecofriendly processes as alternatives to conventional antibiotics or other antimicrobial agents.

Guest Editor

Dr. Helena Felgueiras

Centre for Textile Science and Technology, University of Minho, Campus de Azurém, 4800-058 Guimarães, Portugal

Deadline for manuscript submissions

closed (31 July 2025)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/176588

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

